Which of the following best describes where ME practices?
Academic institution/tertiary hospital
Community hospital/private clinics
Other
Which of the following best describes ME’s area of specialty?
Medical Oncology – primarily breast cancer
Medical Oncology – general/solid tumors
Surgical Oncology – breast cancer
Radiation/Clinical Oncology – breast cancer
Gynecologist/Gynecologic Oncologist
Other
In the last month/4 weeks of ME’s outpatient clinics, what percentage of newly diagnosed patients had early breast cancer (EBC) thought to be completely resectable?
＞90%
70% to 90%
50% to 70%
＜50%
Of the patients diagnosed with EBC in your practice(s) each month, what percentage of tumors are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-)?
25%
25% to 50%
50% to 75%
≥75%
For those patients with HR+, HER2– EBC, how often is adjuvant treatment likely offered?
Physician/Patient Journey
Which of the following factors and/or tools do you MAINLY use to determine risk of disease recurrence and adjuvant treatment modality for patients diagnosed with HR+, HER2– EBC?
Tumor grade with biomarker data (eg, ER, PgR, HER2, Ki67)
Mainly multigene panel (eg, Oncotype DX or MammaPrint)
AJCC older editions (anatomic TNM staging only)
AJCC 8th edition (anatomic TNM staging + tumor grade, biomarkers, and gene expression)
Other
Which patient characteristic would you consider MOST important when deciding whether to initiate adjuvant treatment(s)?
Positive nodal status
Stage II or III
Ki67 ≥20%
Other
Based on the patient characteristic you’ve identified in the previous question ,which of the following would you consider the MOST important part of your standard treatment approach for these patients?
Chemotherapy
ET
Targeted therapy (eg, CDK4/6 inhibitor + ET)
Other
[Select ALL that apply]Which patients with node-negative (N0) tumors do you intend to treat with adjuvant therapy to prevent disease progression?
N0 with T2-3
N0 with histologic grade 2-3
N0 with Ki67 ≥20%
Nodal status does not influence my decision to use adjuvant therapy
Other
In your country/region, do you have standardized screening programs to identify patients with EBC?
Yes, and I think the programs are adequate
Yes, but I think the programs are inadequate
No
Which specialty in your institution initiate patients on treatment with adjuvant therapies the MOST?
Medical oncologists
Clinical/radiation oncologists
Surgeons/breast surgeons/gynecologists
Often initiated by other institutions/hospitals
Others
What international BC guideline do you refer to the MOST when considering adjuvant treatment?
NCCN
ESMO
St. Gallen
Other
[Select ALL that apply] Have you been involved in any of the following settings to gain experience using CDK4/6 inhibitors in EBC?
Clinical trials
MAP/compassionate use
Registry/postmarketing surveillance/postauthorization safety study
Other
Why do you think CDK4/6 inhibitors may work in the adjuvant setting?
This is mainly due to cancer cell senescence induced by CDK4/6 inhibitors
This is mainly due to the immunomodulatory effect of CDK4/6 inhibitors.
This is mainly due to their effect on cell cycle progression, leading to cell cycle arrest.
Other
Considering tolerability, which of the following adverse events do you consider having the MOST impact on patient adherence to CDK4/6 inhibitor treatment in the adjuvant setting?
Fatigue
Diarrhea
Nausea/vomiting
Liver toxicity
Other
How often have you been consulted by payers, health authorities, or peers on treatment choice/guidelines in EBC?
At least once every month
At least once every year
Rarely
I have not been consulted on treatment choice/guidelines in EBC
If you have used a CDK4/6 inhibitor (+ ET) in routine clinical practice in EBC (outside clinical trials), how satisfied do you think your patients have been with their treatment experience?
Satisfied
Somewhat satisfied
Not really satisfied
In your opinion, which of the following poses the greatest challenge with incorporating the currently approved CDK4/6 inhibitor + ET adjuvant therapy into your practice(s)?
Limited patient population
Tolerability
Additional monitoring which adds burden to already busy clinic
Initiation of CDK4/6 inhibitor involves different specialty in my Institution
Other
When selecting a CDK4/6 inhibitor (+ ET) in EBC, which of the following has the greatest impact in your decision-making process?
Broad indication
Tolerability
Impact on QOL
Patient preference
Other
When considering a CDK4/6 inhibitor (+ ET) in the EBC setting, how long do you think would be the ideal duration of treatment? Why?
2 years (include reason in choice d)
3 years (include reason in choice d)
5 years (include reason in choice d)
Please type the reason for your choice
Which metastatic breast cancer (mBC) treatment modality would you consider the MOST appropriate for patients who had disease recurrence >12 months after completion of adjuvant CDK4/6 inhibitor (+ ET) therapy?
Chemotherapy
Rechallenge with same CDK4/6i (+ ET)
Rechallenge with different CDK4/6i (+ ET)
Other